ONX-0914

ONX-0914 has been studied in 3 papers since 2022: none in people yet, 2 in animals, 1 review; 1 in the past year. The research so far is in animals. The newest story, Nov 4, 2026: “Clearing protein deposits restored liver regrowth in aged mice”.

Intervention

3 papers study it5 findingsUpdated Nov 1, 2026

PubChem

1 new paper in 30 daysSee all 3 papers on ONX-0914

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

1 lab in 1 country

Funder: European Commission

Animals2

What did studies of ONX-0914 find?

Studies of ONX-0914 measured 4 outcomes; the most studied are inflammation (2 studies), muscle fibrosis (1) and oxidative stress and ROS signaling (1).

Inflammation

downin mice1downin reviews1

2 studies

ONX-0914 inhibits inflammation in preclinical models of autoimmune myositis and muscle atrophy.
“Selective IMP inhibitors, such as ONX 0914 and KZR-616, display potent anti-inflammatory effects in preclinical models of autoimmune myositis and muscle atrophy.”
Reviewin preclinical models of autoimmune myositis and muscle atrophy
Immunoproteasomes in Skeletal Muscle Pathologies: Emerging Roles, Conflicting Evidence, and Future Directions
CellsOct 12, 2025
ONX-0914 decreases inflammation in mice (mdx mice).
“It modulates inflammatory markers both in skeletal and cardiac muscle”
Animalsmdx miceskeletal and cardiac muscle
Immunoproteasome Inhibition Ameliorates Aged Dystrophic Mouse Muscle Environment
International journal of molecular sciencesNov 24, 2022

Latest

1 paper in 12 months

Cell ReportsNov 4

Clearing protein deposits restored liver regrowth in aged mice

Experiments in aged mice found that clearing abnormal protein deposits around blood vessels with anselamimab restored liver regeneration after partial liver removal.Experiments in aged mice found that clearing abnormal protein deposits around blood vessels with anselamimab restored liver regeneration after partial liver removal.

Mouse studyInterventions